These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 16278815)
21. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707 [TBL] [Abstract][Full Text] [Related]
22. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280 [TBL] [Abstract][Full Text] [Related]
23. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of p53 in Barrett's oesophagus. Krishnadath KK; van Blankenstein M; Tilanus HW Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817 [TBL] [Abstract][Full Text] [Related]
32. A quantitative promoter methylation profile of prostate cancer. Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627 [TBL] [Abstract][Full Text] [Related]
33. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717 [TBL] [Abstract][Full Text] [Related]
34. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization. van Dekken H; Vissers CJ; Tilanus HW; Tanke HJ; Rosenberg C J Pathol; 1999 Jul; 188(3):263-6. PubMed ID: 10419593 [TBL] [Abstract][Full Text] [Related]
35. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study. Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672 [TBL] [Abstract][Full Text] [Related]
36. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Quera R; O'Sullivan K; Quigley EM Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424 [TBL] [Abstract][Full Text] [Related]
37. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671 [TBL] [Abstract][Full Text] [Related]
38. [Risk stratification in medulloblastoma: screening for molecular markers]. Ebinger M; Senf L; Scheurlen W Klin Padiatr; 2006; 218(3):139-42. PubMed ID: 16688669 [TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus]. Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305 [TBL] [Abstract][Full Text] [Related]
40. Genetic diversity during the development of Barrett's oesophagus-associated adenocarcinoma: how, when and why? Graham TA; McDonald SA Biochem Soc Trans; 2010 Apr; 38(2):374-9. PubMed ID: 20298186 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]